CIRM Funded Clinical Trials

Phase I Study of IL13Rα2-Targeting CAR T Cells After Lymphodepletion for Children with Refractory or Recurrent Malignant Brain Tumors


Leo Wang
Disease Area: 
Investigator:
CIRM Grant:
CLIN2-12153 (Pre-Active)
Award Value:
$8,401,309
Trial Sponsor:
Beckman Research Institute of City of Hope
Trial Stage: 
Phase 1
Trial Status: 
Recruiting
Targeted Enrollment:
18
ClinicalTrials.gov ID:
Details: 

City of Hope will conduct a clinical trial for children with malignant brain tumors.  Brain tumors are the most common solid tumor of childhood, with roughly 5,000 new diagnoses per year in the United States.

The team will treat pediatric patients with aggressive brain tumors using chimeric antigen receptor (CAR) T cell therapy.  The CAR T therapy involves obtaining a patient’s own T cells, which are an immune system cell that can destroy foreign or abnormal cells, and modifying them so that they are able to identify and destroy the brain tumors.  The aim of this approach is to improve patient outcome.

Design: 

Phase 1 Clinical Trial 

Goal: 

Demonstrate safety and tolerability.